Form 4 for JAZZ Jazz Pharmaceuticals plc
Accepted 2025-12-09 00:00:00 ET · period of report 2025-12-05 · accession 0001784606-25-000007 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-12-09 | 2025-12-05 | JAZZ | Carr Patricia | SVP, CAO | S - Sale+OE | $171.20 | -4,660 | 7,012 | -40% | -$797.8K |
| D | 2025-12-09 | 2025-12-05 | JAZZ | Carr Patricia | SVP, CAO | M - OptEx | $140.67 | +4,500 | 11.5K | +64% | +$633.0K |
| D | 2025-12-09 | 2025-12-05 | JAZZ | Carr Patricia | SVP, CAO | M - OptEx | $0.00 | -4,500 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Ordinary Shares | 2025-12-05 | S | D | 160 | $171.11 | 7,012 | D | — | — | (F1) The Reporting Person acquired 160 ordinary shares under a Section 423 Employee Stock Purchase Plan on November 28, 2025. |
| 2 | Common | Ordinary Shares | 2025-12-05 | S | D | 4,500 | $171.20 | 7,012 | D | — | — | (F2) Reflects sales of ordinary shares executed in multiple transactions at prices ranging from $171.2001 to $171.2601. The price reported reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the sales were effected. |
| 3 | Common | Ordinary Shares | 2025-12-05 | M | A | 4,500 | $140.67 | 11,512 | D | — | — | |
| 4 | Derivative | Non-Qualified Stock Option (right to buy) | 2025-12-05 | M | D | 4,500 | $0.00 | 0 | D | $140.67 · — to 2028-02-29 | 4,500 Ordinary Shares | (F3) These options were granted pursuant to the Issuer's 2011 Equity Incentive Plan. The ordinary shares subject to these options vest over four years measured from the grant date, March 1, 2018, with 1/4th vesting on the first anniversary of the grant date and the remainder vesting in 36 equal monthly installments thereafter. The option fully vested as of March 1, 2022. |